The Vectra® 3 automated quantitative pathology imaging system accurately detects and measures weakly expressing and overlapping biomarkers within a single H&E, IHC or IF intact FFPE tissue section or TMA.
Please enter valid quantity
Please login to add favorites
NULL OR EMPTY CART
You successfully added item(s) to your cart
The Vectra® 3 automated quantitative pathology imaging system is available as a 6-slide or 200-slide configuration. Both accurately detect and measure weakly expressing and overlapping biomarkers within a single H&E, IHC or IF intact FFPE tissue section or TMA. Vectra and inForm® software analysis combine the power of multiplexed biomarker imaging and quantitative analysis within a familiar digital pathology workflow to accelerate your cancer immunology research.
Tissue sections or TMAs can be labeled with immunofluorescent (IF) or immunohistochemical (IHC) stains, or with conventional stains such as H&E and trichrome. When using IF or IHC stains, multiple proteins can be measured on a per tissue, per cell, or per cell compartment (e.g. nuclear, cytoplasmic) basis - even when signals are spectrally similar, are located in the same cellular compartment or are obscured by autofluorescence.
Vectra 3 introduces the Phenochart™ whole slide contextural viewer with annotation capability into the digital workflow, where pathologists and technicians can navigate around slides and identify areas of interest for high-resolution multispectral acquisition. The system features automated slide handling, multispectral imaging technology, and unique pattern-recognition-based image analysis enabling quantitative data acquisition for up to 200 slides within a single batch run. It accurately measures protein and biomarker expression and morphometric characteristics in intact tissue sections for translational studies.
Disclaimer: For research use only. Not for use in diagnostic procedures.
You have selected:
|Resource Type||File Name||File Format|
|Brochure||Phenoptics™ Research Solutions||PDF 11 MB|
|Product Note||Quantitative Pathology Imaging and Analysis||PDF 2 MB|
|Product Note||Vectra 3: Quickening the Pace of Understanding||PDF 6 MB|
|Application Note||Detecting Phenotypical Subgroups in Breast Cancer using Multiplexed Protein Expression Analysis in Intact Tissue Sections||PDF 2 MB|
|Poster||Understanding immune phenotypes and their spatial relationships to breast adenocarcinoma||PDF 1 MB|
|Product Info||Let's Rid the World of Ribbons - Infographic||PDF 822 KB|
|E-book||Download Phenoptics Research Solutions E-book||Link|
|Poster||Evaluation Of Tumor Immune Infiltrate as a Determinant of Response to Neo-Adjuvant Lapatinib||Link|
|Scientific Paper||NEJM: Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma||Link|
|Scientific Paper||Esbona, Karla, et al. "COX-2 modulates mammary tumor progression in response to collagen density." Breast Cancer Research 18.1 (2016)||Link|
|Scientific Paper||Feng, Zipei, et al. "Multispectral Imaging of T and B Cells in Murine Spleen and Tumor." The Journal of Immunology 196.9 (2016): 3943-3950||Link|
|Scientific Paper||Woods, Katherine, et al. "Mismatch in epitope specificities between IFN? inflamed and uninflamed conditions leads to escape from T lymphocyte killing in melanoma." Journal for immunotherapy of cancer 4.1 (2016)||Link|
|Scientific Paper||Huang, Fangjin, et al. "Quantitative imaging for development of companion diagnostics to drugs targeting HGF/MET." The Journal of Pathology: Clinical Research (2016)||Link|
|Scientific Paper||Ören, Bilge, et al. "Tumour stroma-derived lipocalin-2 promotes breast cancer metastasis." The Journal of Pathology (2016)||Link|
|Scientific Paper||Linch, Stefanie N., et al. "Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T-cell anergy and promotes survival in tumor-bearing mice." Proceedings of the National Academy of Sciences 113.3 (2016): E319-E327||Link|
|Scientific Paper||NEJM: PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma||Link|
|Scientific Paper||Novartis Genoptix Shows Multiplexed IHC Test Better Predicts Immunotherapy Response||Link|
|Scientific Paper||Mlecnik, Bernhard, et al. "The tumor microenvironment and Immunoscore are critical determinants of dissemination to distant metastasis." Science translational medicine 8.327 (2016)||Link|
|Scientific Paper||Nghiem, Paul T., et al. "PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma." New England Journal of Medicine (2016)||Link|
|Software Downloads||Click here to download latest software||Link|
|Story||How Your Immune System Can Fight Cancer||Link|
|Webinar||Using multiplexed IHC to Effectively Navigate the Hidden Clues of the Immunological Microenvironment||Link|
|Webinar||Untangling the tumor microenvironment: Illuminating the complex interactions and functions of immune cells||Link|